FLORA AGYEI: Open Payments
NPI 1336446806 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$860 in 47 payments from 11 companies in 2025. Trend: 2023 $1,080 · 2024 $859 · 2025 $860
Food & beverage: $860
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $259 |
| ABBVIE INC. | 15 | $154 |
| Lundbeck LLC | 4 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $96 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Neurocrine BioSciences, Inc. | 2 | $31 |
| Sage Therapeutics, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, AUSTEDO XR, FANAPT, COBENFY, ABILIFY MAINTENA, UZEDY.
Industry payments across WI — which companies pay providers there.
